- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Perspective Therapeutics Inc (CATX)
Perspective Therapeutics Inc stock price live, this page displays NYSE CATX stock exchange data. View the CATX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Perspective Therapeutics Inc real time stock price chart below.
What Is the Perspective Therapeutics Inc Stock Price Today?
The Perspective Therapeutics Inc stock price today is 3.4600.
What Is the Stock Symbol for Perspective Therapeutics Inc?
The stock symbol for Perspective Therapeutics Inc is ""CATX.""
What Stock Exchange Does Perspective Therapeutics Inc Trade On?
Perspective Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Perspective Therapeutics Inc a Good Stock to Buy?
Determining whether Perspective Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CATX quote. (ISIN: US46489V3024)
What Is the Perspective Therapeutics Inc Stock Price Today?
The Perspective Therapeutics Inc stock price today is 3.4600.
What Is the Stock Symbol for Perspective Therapeutics Inc?
The stock symbol for Perspective Therapeutics Inc is ""CATX.""
What Stock Exchange Does Perspective Therapeutics Inc Trade On?
Perspective Therapeutics Inc is listed and trades on the NYSE stock exchange.
Is Perspective Therapeutics Inc a Good Stock to Buy?
Determining whether Perspective Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CATX quote. (ISIN: US46489V3024)
Fair Value
An estimate of a Perspective Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.4150
3.6900
52 wk Range
1.6000
16.5500
CATX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CATX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Perspective Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.41503.6900
52 wk Range
1.600016.5500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CATX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Perspective Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
13.9643
Upside
+303.59%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Perspective Therapeutics Inc For: 13 August
- Investing.com
- Form 8K Perspective Therapeutics Inc For: 1 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Perspective Therapeutics Inc Company Profile
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics Inc SWOT Analysis
Radiopharmaceutical Pionee | Perspective Therapeutics leads in targeted cancer therapies with its innovative lead-specific chelator technology and diverse pipeline, positioning itself as a key player in the RPT space. |
Clinical Progress | Explore the company's advancing VMT-α-NET program, with expanded patient enrollment and promising initial safety profiles, signaling confidence in its therapeutic potential. |
Financial Outlook | Analysts maintain a strong buy consensus with an average price target of $16, balancing short-term caution against long-term optimism for CATX's platform and pipeline. |
Strategic Advantages | Delve into CATX's decentralized manufacturing strategy and robust patent estate, potentially offering improved efficiency and a competitive edge in commercialization. |
Compare CATX to Peers and Sector
Metrics to compare | CATX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCATXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −0.7x | −0.6x | |
PEG Ratio | −0.76 | −0.02 | 0.00 | |
Price/Book | 1.0x | 1.0x | 2.6x | |
Price / LTM Sales | 209.3x | 9.0x | 3.3x | |
Upside (Analyst Target) | 294.0% | 280.3% | 37.4% | |
Fair Value Upside | Unlock | 26.6% | 4.5% | Unlock |
Analyst Ratings
13 Buy
1 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.9643
(+303.59% Upside)
Earnings
Latest Release
Aug 13, 2025
EPS / Forecast
-0.29 / -0.29
Revenue / Forecast
290.00K / 185.86K
People Also Watch
FAQ
What Stock Exchange Does Perspective Therapeutics Trade On?
Perspective Therapeutics is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Perspective Therapeutics?
The stock symbol for Perspective Therapeutics is "CATX."
What Is the Perspective Therapeutics Market Cap?
As of today, Perspective Therapeutics market cap is 260.29M.
What Is Perspective Therapeutics's Earnings Per Share (TTM)?
The Perspective Therapeutics EPS (TTM) is -1.33.
When Is the Next Perspective Therapeutics Earnings Date?
Perspective Therapeutics will release its next earnings report on 17 Nov 2025.
From a Technical Analysis Perspective, Is CATX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Perspective Therapeutics Stock Split?
Perspective Therapeutics has split 1 times.
How Many Employees Does Perspective Therapeutics Have?
Perspective Therapeutics has 139 employees.
What is the current trading status of Perspective Therapeutics (CATX)?
As of 25 Aug 2025, Perspective Therapeutics (CATX) is trading at a price of 3.46, with a previous close of 3.68. The stock has fluctuated within a day range of 3.42 to 3.69, while its 52-week range spans from 1.60 to 16.55.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.